Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29445407 | 1.00 | MAPK1 (0.44) | MAPK1TSHRAHRCHUKVCAM1 | |
| SCHEMBL12161659 | 0.82 | MAPK1 (0.42) | MAPK1TSHRAHRCHUKVCAM1 | |
| SCHEMBL985995 | 0.82 | AHR (0.51) | MAPK1TSHRAHRALDH1A1GPR35 | |
| SCHEMBL203312 | 0.82 | INPPL1 (0.46) | MAPK1TSHRAHRCHUKVCAM1 | |
| SCHEMBL29780392 | 0.82 | AHR (0.51) | MAPK1TSHRAHRALDH1A1GPR35 | |
| SCHEMBL30408800 | 0.80 | TDP1 (0.41) | MAPK1TSHRAHRVCAM1PDE7A | |
| SCHEMBL422756 | 0.80 | ERN1 (0.39) | MAPK1TSHRVCAM1POLBALDH1A1 | |
| SCHEMBL30230909 | 0.80 | SMN1; SMN2 (0.54) | MAPK1TSHRPOLBALDH1A1L3MBTL1 | |
| SCHEMBL541340 | 0.80 | SMN1; SMN2 (0.54) | MAPK1TSHRPOLBALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL14989233 | 0.80 | AHR (0.50) | MAPK1TSHRAHRALDH1A1GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 384 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107176952-A | A kind of synthetic method of imidazole derivative | 湖南华腾制药有限公司 | 2017-09-19 | — | — | CN | claimed |
| JP-63225631-A | — | — | None | — | — | JP | disclosed |
| US-20260097034-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LTD (HK) | 2026-04-09 | — | — | US | disclosed |
| US-12522697-B2 | Polyarylene sulfide, and purification method and production method therefor | DIC CORPORATION (JP) | 2026-01-13 | — | — | US | disclosed |
| EP-4646263-A1 | SPRK1 INHIBITORS AND METHODS OF USE | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) | 2025-11-12 | — | — | EP | disclosed |
| US-12458642-B2 | Metalloenzyme inhibitor compounds | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2025-11-04 | — | — | US | disclosed |
| US-12441755-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2025-10-14 | — | — | US | disclosed |
| EP-4561561-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | Septerna, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250145825-A1 | POLYARYLENE SULFIDE RESIN COMPOSITION, MOLDED ARTICLE, AND METHODS FOR PRODUCING THESE | DIC CORPORATION (JP) | 2025-05-08 | — | — | US | disclosed |
| EP-0302218-A1 | Process for producing polyarylene sulfide | IDEMITSU PETROCHEMICAL CO. LTD. (JP) | 1989-02-08 | — | — | EP | disclosed |
| EP-0296250-A1 | POLYARYLENE SULFIDE AND PROCESS FOR ITS PRODUCTION | IDEMITSU PETROCHEMICAL COMPANY LIMITED (JP) | 1988-12-28 | — | — | EP | disclosed |
| JP-S63225631-A | PRODUCTION OF POLYARYLENE SULFIDE | IDEMITSU PETROCHEM CO LTD | 1988-09-20 | — | — | JP | disclosed |
| US-4759796-A | Used together with a carrier and other adjuvant | CIBA-GEIGY CORPORATION (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0248968-A1 | (R)-2-[4-(5-chloro-3-fluoropyridin-2-yloxy)-phenoxy]-propionic acid propynyl ester endowed with a herbicidal activity | CIBA-GEIGY AG (CH) | 1987-12-16 | — | — | EP | disclosed |
| US-4713109-A | 2-(4-(5-chloro-3-fluoropyridin-2-yloxy)phenoxy)-propionic acid-propynyl ester with herbicidal activity | CIBA GEIGY CORPORATION (US) | 1987-12-15 | — | — | US | disclosed |
| US-4640703-A | CONTROLLING GRASSES IN CROPS | CIBA-GEIGY CORPORATION (US) | 1987-02-03 | — | — | US | disclosed |
| EP-0178260-A2 | Process for the preparation of fluorinated pyridine derivatives | CIBA-GEIGY AG (CH) | 1986-04-16 | — | — | EP | disclosed |
| EP-0148119-A2 | Amides of 2-phenoxypropionic acid | CIBA-GEIGY AG (CH) | 1985-07-10 | — | — | EP | disclosed |
| US-4247556-A | 7-Azabenzimidazoles with basic side chains and use thereof | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1981-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | MAPK1 301/4885TSHR 2869/4885AHR 2838/4885 |
| US-12458642-B2 | Metalloenzyme inhibitor compounds | CYP11B2, CYP11B1, HSD11B2 | MAPK1 1060/4885TSHR 2512/4885AHR 2026/4885 |
| US-12441755-B2 | Galactoside inhibitor of galectins | LGALS1, LGALS3, LGALS2 | MAPK1 201/4885TSHR 1602/4885AHR 3318/4885 |
| US-20260097034-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CPN1, TPP1, DPP4 | MAPK1 2739/4885TSHR 1191/4885AHR 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.